Brief ReportsCross-sectional Comparison of Fasting Lipids in Normoglycemic Patients With Schizophrenia During Chronic Treatment With Olanzapine, Risperidone, or Typical AntipsychoticsHardy, Thomas A. MD, PhD; Marquez, Eva MS; Kryzhanovskaya, Ludmila MD, PhD; Taylor, Cindy C. PhD; Cavazzoni, Patrizia MDAuthor Information Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN. Received April 27, 2005; accepted after revision May 4, 2006. Address correspondence and reprint requests to Thomas Hardy, MD, PhD, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 2138, Indianapolis, IN 46285. E-mail: [email protected]. Journal of Clinical Psychopharmacology: August 2006 - Volume 26 - Issue 4 - p 405-408 doi: 10.1097/01.jcp.0000227705.56870.06 Buy Metrics Abstract We compared fasting lipids and other metabolic parameters in 211 normoglycemic patients meeting the DSM-IV diagnosis of schizophrenia or schizoaffective disorder undergoing continuous treatment with olanzapine, risperidone, or typical antipsychotics for at least 1 year. Blood samples were obtained after an 11-hour (±1 h) observed fast. Olanzapine-treated patients had significantly higher mean fasting triglyceride levels (2.3 ± 1.8 mmol/L) than risperidone- (1.7 ± 0.9 mmol/L, P = 0.022), but not typical antipsychotic-treated patients (1.8 ± 1 mmol/L). There were no significant differences in total low-density (LDL-C) or high-density lipoprotein cholesterol levels. Apolipoprotein-B and very low density lipoprotein cholesterol levels were significantly higher in the olanzapine- versus risperidone-treated patients, but there were no significant differences between olanzapine- and typical antipsychotic-treated patients. Treatment groups did not differ significantly in LDL particle size, the prevalence of an "atherogenic" lipid profile, or estimated insulin sensitivity. Although interpretation of this study is limited by the cross-sectional study design, it provides additional insight concerning the relationship between antipsychotic use and plasma lipid parameters in this population. © 2006 Lippincott Williams & Wilkins, Inc.